Channel Therapeutics Corporation announced that it achieved its endpoints in two pre-clinical in vivo models of the Company’s nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration. “We are very pleased with the results, which potentially demonstrate that nerve blocks with our NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain,” stated Dr. Eric Lang, Chief Medical Officer of Channel. “Additionally, we believe this drug has the potential to improve on existing postoperative therapeutic options while opening the door for success with our other programs,” concluded Dr. Lang.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRO:
- Chromocell changes name to Channel Therapeutics, provides program updates
- Chromocell Therapeutics Rebrands to Focus on Pain Treatments
- Chromocell Therapeutics Merges into Channel Therapeutics
- Chromocell unveils injectable depot program for treating surgical pain
- Chromocell Therapeutics announces amendment to stock repurchase plan